ReviewFrontiers in pharmacology2026
Research progress on the molecular mechanisms of chlorogenic acid's pharmacological effects and its advanced drug delivery systems.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Recent Advances in Chlorogenic Acids for Food Preservation and Shelf-Life Extension.Antioxidants (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chlorogic acid (CGA), a prevalent polyphenol formed in plants, is recognized for its broad spectrum of biological activities, including potent antioxidant, anti-inflammatory, antimicrobial, andmetabolic regulatory effects. This review synthesizes evidence demonstrating CGA's therapeutic potential across various conditions, such as hypertension, gout, atherosclerosis, and metabolic disorders. Key mechanisms involve neutralizing reactive oxygen species, modulating critical signaling pathways like TLR2/NF-κB and MAPK, enhancing insulin sensitivity, and influencing endothelial function by boosting NO production via eNOS phosphorylation. Despite these promising attributes, CGA's clinical translation is hindered by significant bioavailability challenges stemming from poor solubility, rapid metabolism, and instability in physiological environments. To address these limitations, innovative drug delivery systems are being investigated. These systems, including polymeric nanoparticles, liposomes, micelles, and hydrogels, offer strategies to encapsulate CGA, thereby protecting it from degradation, improving its dissolution properties, and enabling controlled or targeted release at specific sites of action. Such advancements in delivery technology are crucial for enhancing CGA's stability and bioavailability, ultimately bridging the gap between its demonstrated
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.